Shisi Pharmaceutical Group announced that the Group's salfiamide mesylate has been approved by the China National Drug Administration for registration as an active ingredient for use in marketed formulations, and is the first domestic company to be approved. Salfamide mesylate is mainly used to treat Parkinson's disease and is used in combination with other Parkinson's drugs such as levodopa.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.